Condition-Specific Health
Chronic Pain Research Gap in Women Signals Formulation Opportunity
Pan-Canadian strategy roadmap identifies research and care gaps — opening a lane for evidence-backed nutraceutical and …
Condition-Specific Health 84 stories
Condition-Specific Health
Chronic Pain Gap in Women and Veterans Signals Formulation Opportunity
Pan-Canadian strategy roadmap identifies research, care, and policy gaps — opening space for evidence-backed nutraceuti…
Condition-Specific Health
Gildeuretinol Enters Phase 3 Trial for Stargardt Disease
The deuterium-stabilized vitamin A analog moves into global pivotal testing, raising questions about regulatory classif…
Condition-Specific Health
Neridronate Enters Phase 3 Trial for Rare Pain Condition CRPS-1
With an estimated 65,000 new U.S. cases annually, CRPS-1 represents a significant unmet need that could open upstream i…
Condition-Specific Health
Telitacicept Wins China NMPA Nod for Sjögren's Disease
The NMPA approval marks the first regulatory green light globally for a Sjögren's Disease-specific indication, spotligh…
Condition-Specific Health
Telitacicept Wins China NMPA Nod for IgA Nephropathy
The conditional approval marks a regulatory milestone for dual cytokine inhibition in a kidney disease with limited the…
Condition-Specific Health
Deutetrabenazine Data Show Long-Term TD Symptom Gains
New findings from Psych Congress Elevate underscore neurological symptom management advances, a space adjacent to emerg…
Condition-Specific Health
Teverelix® Phase 2b Filing Targets High-CV-Risk Prostate Cancer Niche
The underserved patient segment represents an estimated $4 billion annual market opportunity, according to the company.
Condition-Specific Health
Tegoprubart Islet Transplant Trial Posts Updated T1D Data
Immunosuppression mechanism under scrutiny as transplant tolerance data edges closer to clinical relevance for metaboli…
Condition-Specific Health
FDA Accepts BLA for Vedolizumab Biosimilar AVT16 from Alvotech
The gut-health biologics pipeline inches forward as a vedolizumab biosimilar clears a key regulatory milestone — with i…
Condition-Specific Health
FDA Accepts BLA for AVT16, Vedolizumab Biosimilar Targeting IBD
The gut-targeted integrin inhibitor category draws biosimilar competition as regulators advance interchangeability revi…
Condition-Specific Health
FDA Accepts BLA for AVT16, Proposed Vedolizumab Biosimilar
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…